​

Dyne Therapeutics (DYN) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

DYN Stock Forecast

Dyne Therapeutics (DYN) stock forecast, based on 14 Wall Street analysts, predicts a 12-month average price target of $35.20, with a high of $50.00 and a low of $24.00. This represents a 123.21% increase from the last price of $15.77.

$15 $22 $29 $36 $43 $50 High: $50 Avg: $35.2 Low: $24 Last Closed Price: $15.77

DYN Stock Rating

Dyne Therapeutics stock's rating consensus is Buy, based on 14 Wall Street analysts. The breakdown includes 1 Strong Buy (7.14%), 11 Buy (78.57%), 1 Hold (7.14%), 1 Sell (7.14%), and 0 Strong Sell (0.00%).

Buy
Total 14 0 1 1 11 1 Strong Sell Sell Hold Buy Strong Buy

DYN Price Target Upside V Benchmarks

TypeNameUpside
StockDyne Therapeutics123.21%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts41025
Avg Price Target$41.50$39.00$37.28
Last Closing Price$15.77$15.77$15.77
Upside/Downside163.16%147.31%136.40%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 26313--117
Sep, 263131--17
Aug, 263131--17
Jul, 263122--17
Jun, 263112--16
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 30, 2026Paul MatteisStifel Nicolaus$37.00$16.18128.68%134.62%
Sep 30, 2026H.C. Wainwright$32.00$16.2197.41%102.92%
Sep 30, 2026Andrew TsaiJefferies$50.00$16.21208.45%217.06%
Sep 29, 2026Edward TenthoffPiper Sandler$47.00$16.15191.02%198.03%
Sep 09, 2026Morgan Stanley$36.00$19.7882.00%128.28%
Sep 09, 2026RBC Capital$30.00$19.7252.13%90.23%
Sep 09, 2026Brian SkorneyRobert W. Baird$26.00$20.3128.02%64.87%
Sep 08, 2026Michael FreemanRaymond James$37.00$20.4780.75%134.62%
Aug 17, 2026Andrew FeinH.C. Wainwright$50.00$25.7094.55%217.06%
Jul 31, 2026Morgan Stanley$45.00$24.6482.63%185.35%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 30, 2026H.C. WainwrightBuyBuyhold
Sep 30, 2026Cantor FitzgeraldOverweightOverweighthold
Sep 30, 2026JefferiesBuyBuyhold
Sep 29, 2026Piper SandlerOverweightOverweighthold
Sep 09, 2026RBC CapitalOutperformOutperformhold
Sep 08, 2026Raymond JamesStrong BuyStrong Buyhold
Aug 17, 2026H.C. WainwrightBuyBuyhold
Jul 23, 2026Cantor FitzgeraldOverweightinitialise
Jun 26, 2026Cowen & Co.BuyBuyinitialise
May 13, 2026BernsteinMarket PerformMarket Performhold

Financial Forecast

EPS Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-3.95$-3.37$-3.47---
Avg Forecast$-3.78$-3.47$-3.76$-3.83$-3.12$-1.16
High Forecast$-3.61$-3.16$-2.83$-3.10$-1.76$-1.16
Low Forecast$-3.95$-3.84$-4.75$-4.79$-3.92$-1.16
Surprise %4.50%-2.88%-7.71%---

Revenue Forecast

$0 $110M $220M $330M $440M $550M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast--$833.33K$9.56M$192.28M$500.80M
High Forecast--$833.33K$9.56M$192.28M$500.80M
Low Forecast--$833.33K$9.56M$192.28M$500.80M
Surprise %------

Net Income Forecast

$-450M $-370M $-290M $-210M $-130M $-50M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-235.94M$-317.42M$-446.21M---
Avg Forecast$-225.57M$-208.96M$-226.32M$-235.37M$-169.58M$-69.23M
High Forecast$-215.66M$-188.82M$-169.04M$-184.84M$-105.33M$-69.23M
Low Forecast$-235.48M$-229.11M$-283.60M$-285.89M$-233.82M$-69.23M
Surprise %4.60%51.90%97.16%---

DYN Forecast FAQ

Is Dyne Therapeutics stock a buy?

Dyne Therapeutics stock has a consensus rating of Buy, based on 14 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 11 Buy, 1 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Dyne Therapeutics is a favorable investment for most analysts.

What is Dyne Therapeutics's price target?

Dyne Therapeutics's price target, set by 14 Wall Street analysts, averages $35.2 over the next 12 months. The price target range spans from $24 at the low end to $50 at the high end, suggesting a potential 123.21% change from the previous closing price of $15.77.

How does Dyne Therapeutics stock forecast compare to its benchmarks?

Dyne Therapeutics's stock forecast shows a 123.21% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Dyne Therapeutics over the past three months?

  • October 2026: 17.65% Strong Buy, 76.47% Buy, 0% Hold, 0% Sell, 5.88% Strong Sell.
  • September 2026: 17.65% Strong Buy, 76.47% Buy, 5.88% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 17.65% Strong Buy, 76.47% Buy, 5.88% Hold, 0% Sell, 0% Strong Sell.

What is Dyne Therapeutics’s EPS forecast?

Dyne Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-3.83, marking a 10.37% increase from the reported $-3.47 in 2025. Estimates for the following years are $-3.12 in 2027, and $-1.16 in 2028.

What is Dyne Therapeutics’s revenue forecast?

Dyne Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $9.56M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $192.28M, and $500.8M for 2028.

What is Dyne Therapeutics’s net income forecast?

Dyne Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-235M, representing a -47.25% decrease from the reported $-446M in 2025. Projections indicate $-170M in 2027, and $-69.233M in 2028.